Selank

A synthetic tuftsin-derived heptapeptide developed in Russia for anxiety-related research.

Early human evidencePeptide research profile

Also known as: TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro

Sources reviewed October 1, 2026 (how we review)

Dosing & scaling, explained

The 200 mcg daily row is an injectable calculator preset. Published human Selank work is predominantly intranasal and cannot validate that route or amount. This is educational source context, not a protocol or recommendation.

How sourced amounts are organized

Starting pointNot clinically establishedNo validated titration window
There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.
Recorded preset200 mcg / dayCalculator library reference
This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.
Higher exposureNo injectable ceiling establishedRisk and uncertainty increase
Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Drug amount and device markings are different quantities. The calculator converts mass into volume, syringe units, or pen clicks.

Patterns described in source material

Daily in the recorded preset
The cadence represented by the recorded calculator presets.
Intranasal courses in regional clinical studies
Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.
No universal schedule
No single schedule has been validated across products or research contexts.

Clinical context

Limited human evidence exists, but it does not establish the in-app injectable regimen.

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze-thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Reported protocols for Selank

What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical, 2 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.

Context	Dose	Frequency	Route	Course	Source
Clinical4 rows
Registered Russian label, Selank 0.15% nasal dropsAdults with anxiety and neurasthenic disorders, as the registered indication is written	2 drops into each nostril of the 0.15% solution (1.5 mg per mL)	3 times daily	Intranasal drops	14 daysA repeat course is described as possible after 1-3 weeks, following consultation with a doctor	Community resource2009
This manufacturer instruction carries the Russian Ministry of Health registration and sets out the only officially sanctioned Selank schedule anywhere. It specifies drops rather than a mass per day, so a figure in micrograms cannot be read directly off the label, and the registration has no FDA or EMA standing.
Comparison with phenazepam in anxiety and somatoform disorders60 patients with phobic anxiety, hypochondriac and somatoform disorders	2.7 mg per day	Divided across the day, as the published abstract describes it	Intranasal	A course of treatment, with assessment continuing after the last doseNone described within the course	Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Mediasphera)2014
The authors reported an anxiolytic effect that persisted for at least 7 days after the last dose plus a mild nootropic effect, and significantly better tolerability than phenazepam. The published abstract gives no numerical comparison of effect size, and the trial was small and open to the researchers who developed the compound.
Comparison with medazepam in generalized anxiety disorder and neurasthenia62 patients, 30 given selank and 32 given medazepam	0.15% intranasal solution; the indexed English abstract states no daily amount	Not stated in the indexed abstract	Intranasal	Not stated in the indexed abstractNot described	Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2008
This is the most-cited human study. Anxiolytic effects were reported as similar to the benzodiazepine comparator, with additional antiasthenic and mild stimulant effects and a rise in serum leu-enkephalin half-life that correlated with anxiety scores. Readers outside Russian are limited to the abstract, which carries no dose, no duration and no effect sizes.
Add-on to phenazepam for anxiety-spectrum disorders70 patients: 40 on selank plus phenazepam and 30 on phenazepam alone	0.15% intranasal solution added to phenazepam; no amount is given in the indexed abstract	Not stated in the indexed abstract	Intranasal alongside oral phenazepam	A treatment course followed by tranquilliser withdrawalAssessment continued after the benzodiazepine was withdrawn	Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2015
Adding selank brought the depression-scale response forward and reduced phenazepam side effects, including attention and memory problems, sedation, sexual disturbance and orthostatic symptoms, both during treatment and after withdrawal. As with the other Russian trials, the published abstract reports no doses and the work comes from the group associated with the compound.
Preclinical2 rows
Preclinical course dosing under chronic stress48 male Wistar rats, half exposed to unpredictable chronic mild stress	300 mcg/kg (5 microlitres into each nostril)	Once daily	Intranasal in saline, alone or with oral diazepam at 1 mg/kg	14 daysNot applicable	Behavioural Neurology (PubMed Central)2017
Under chronic stress, selank alone and selank with diazepam lowered elevated-plus-maze anxiety measures relative to saline, with the combination strongest. In the unstressed group every substance course, including saline, worsened anxiety measures, which the authors read as the dosing procedure itself being a stressor.
Preclinical single-dose gene expression study30 male Wistar rats of about 200 g, in selank, GABA and control groups	300 mcg/kg (6 microlitres of aqueous solution)	Single administration	Intranasal	Frontal cortex sampled 1 hour and 3 hours after dosingNot applicable	Frontiers in Pharmacology (PubMed Central)2016
A single intranasal dose altered expression of genes for GABA receptor subunits and transporters in the frontal cortex, which the authors offer as a mechanism for the benzodiazepine-like clinical effects. The 300 mcg/kg figure is described as the most effective anxiolytic dose from earlier rodent work, and it is the dose used across most Selank animal studies.
Community-reported3 rows
Vendor reproduction of the label with mass figures	Single dose 300-450 mcg (4 to 6 drops); optimal daily total described as 900-2,700 mcg	Split into 3 administrations per day, with a 15-minute gap if the single dose is raised	Intranasal, no more than 2 to 3 drops per nostril at a time	10-14 daysRepeat after 1-3 weeks if needed	Community resource2026
This retailer's instruction sheet converts the label's drop counts into micrograms by stating that one drop is 0.05 mL and contains 75 mcg. The conversion is the seller's own, the mass figures do not appear on the manufacturer instruction, and the page exists to support international mail-order sales.
Dosage chart separating the nasal and subcutaneous routes	About 900 mcg per day calculated from the label; 5 mg in 3.33 mL of bacteriostatic water reproduces the 0.15% concentration	3 administrations per day for the nasal route	Intranasal; the page states it could find no published human subcutaneous protocol	14 days, matching the labelDescribed as convention rather than evidence	Community resource2026
This 2026 chart is unusually candid: it derives 900 mcg per day from 12 labelled drops only by assuming 0.05 mL per drop, says that figure is its own calculation and not printed on any label, and reports that the widely quoted 1,350 mcg per day has no primary source it could verify. It also states that no registered subcutaneous product and no indexed human injection trial exists.
Community subcutaneous and intranasal protocol summary	250-500 mcg per day subcutaneously; 600-2,700 mcg per day intranasally	Once daily for the subcutaneous route; 2 to 3 divided doses for the nasal route	Subcutaneous injection or intranasal spray from a reconstituted vial	4 weeks subcutaneous; 14-21 days intranasal4 weeks off after a subcutaneous course; 1-3 weeks off after a nasal course	Community resource2026
This guide keeps the two routes apart and labels the subcutaneous range as community-reported practice rather than published evidence, while tracing the nasal range to Russian clinical reports. It advises reading the stated micrograms per spray on a given bottle instead of assuming a concentration, and notes that most published evidence covers courses of only 14 to 21 days.

How a course is commonly described

Days 1-7Community-reported
Community guides describe the first week as the point at which anxiety, sleep and energy are tracked, with the compound reported as non-sedating compared with benzodiazepines. Nothing published describes a titration, so the course opens at full strength.
Days 8-14Community-reported
The same guide places a stable response in this window for most people in the published record, and the Russian trials ran courses of roughly this length. Anxiety, sleep, energy and side effects are the tracked measures rather than any laboratory marker.
End of the labelled 14-day courseClinical
The registered Russian instruction ends the course at 14 days and allows a repeat only after 1-3 weeks and after speaking to a doctor. That 14-day structure is the origin of almost every cycling pattern circulating online.
First week after stoppingClinical
The 2014 phenazepam comparison reported that the anxiolytic effect was still present for at least 7 days after the last dose, which is unusual for a compound cleared this quickly and is one reason courses are described as discrete rather than continuous.
Repeat coursesCommunity-reported
Community charts extend the label's gap into longer cycles, typically 14-21 days on and 1-3 weeks off for nasal use or 4 weeks on and 4 weeks off for injection. One 2026 chart states plainly that these schedules are vendor and forum convention rather than findings.

Only the intranasal route has a registered product and a published human literature. Subcutaneous Selank appears in vendor and forum material, with no registered preparation and no indexed human trial using injection.
The clinical evidence base is small, almost entirely Russian-language, and produced by or close to the institute that developed the compound, with limited independent replication and courses rarely longer than 21 days.
Doses in micrograms per day do not appear on the manufacturer instruction, which counts drops. Every microgram figure in circulation depends on an assumed drop volume, so the same label yields different totals depending on who is doing the arithmetic.

Sources for this section (12)

A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders (Russian)Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Mediasphera)2014Clinical
A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disordersZhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2014Clinical
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurastheniaZhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2008Clinical
Optimization of the treatment of anxiety disorders with selankZhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2015Clinical
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in RatsBehavioural Neurology (PubMed Central)2017Preclinical
Selank Administration Affects the Expression of Some Genes Involved in GABAergic NeurotransmissionFrontiers in Pharmacology (PubMed Central)2016Preclinical
Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivoDoklady Biological Sciences (PubMed)2008Preclinical

Plus 5 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.

Overview

Selank is a synthetic seven-residue peptide designed at the Institute of Molecular Genetics of the Russian Academy of Sciences by attaching the proline-glycine-proline tripeptide to the immune peptide tuftsin, which slows enzymatic breakdown. It is registered in Russia as Selank 0.15% nasal drops, an over-the-counter anxiolytic under registration number LRS-003338/09, and is classified there as a tranquilliser rather than a supplement. Human evidence is limited to a small number of Russian-language trials in anxiety, phobic and somatoform disorders, mostly comparing it with benzodiazepines in groups of 60 to 70 patients; it has no FDA or EMA approval and is sold elsewhere as a research chemical. Western community use frequently adopts subcutaneous injection, a route with no registered product and no human protocol in the indexed literature.

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

1
Anxiety symptoms
Small Russian comparative studies examine generalized anxiety and neurasthenia.
2
GABAergic signaling
Animal transcript studies report changes in genes involved in inhibitory neurotransmission.
3
Enkephalin metabolism
Clinical and biochemical work explores enkephalin-related mechanisms.
4
Stress and cognition
Preclinical studies examine behavior, learning, and stress adaptation.

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

Human
Small active-comparator study
A 62-patient study compared Selank with medazepam and reported similar anxiety-scale improvement.
Animal
GABA-related gene expression
Rat frontal-cortex studies found broad transcriptional changes after Selank administration.
Review
Independent replication gap
Modern, preregistered, multicenter trials outside the originating network are lacking.

Amounts recorded for Selank

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

1
Dose · lower endpointSign in for schedule, duration and source context.
100 mcg
2
Recorded referenceSign in for schedule, duration and source context.
200 mcg
3
Dose · upper endpointSign in for schedule, duration and source context.
500 mcg

Chemistry identifiers

Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.

Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Also listed as

TP-7, Selanc, Thr-Lys-Pro-Arg-Pro-Gly-Pro, UNII TS9JR8EP1G, TP-7 (diacetate), DTXSID701029276, HY-105042, Threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-proline

InChIKey

JTDTXGMXNXBGBZ-YVHUGQOKSA-N

Origin / design

Extended analogue of the immunomodulatory peptide tuftsin

IUPAC name

(2S)-1-[2-[[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid

Limitations and unknowns

Important limitations

The main clinical report is small, regionally concentrated, and not a modern large placebo-controlled trial.
Regulatory status differs internationally and no FDA-approved product exists.
A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
Route, formulation, and population can make results from one study inapplicable to another use.

Sources

2 curated references, each with its journal, year and study model, plus 5 community resources reported but not linked.

Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurastheniaZhurnal Nevrologii i Psikhiatrii2008Human
Selank administration affects the expression of genes involved in GABAergic neurotransmissionFrontiers in Pharmacology2016Animal

How sourced amounts are organized

Patterns described in source material

Storage, handling and interpretation

How a course is commonly described

What researchers are exploring

Anxiety symptoms

GABAergic signaling

Enkephalin metabolism

Stress and cognition

Small active-comparator study

GABA-related gene expression

Independent replication gap

Sequence

Also listed as

InChIKey

Origin / design

Important limitations